Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy

被引:34
作者
Chou, Shang-Yu [1 ]
Yen, Shao-Lun [5 ]
Huang, Chao-Cheng [2 ]
Huang, Eng-Yen [1 ,3 ,4 ,6 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Dept Pathol, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
[3] Xiamen Chang Gung Hosp, Dept Radiat Oncol, 123 Xiafei Rd, Fujian, Peoples R China
[4] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, 259 Wenhua 1st Rd, Taoyuan, Taiwan
[5] China Med Univ, An Nan Hosp, Dept Pathol, 66,Sec 2,Changhe Rd, Tainan 709, Taiwan
[6] Kaohsiung Chang Gung Mem Hosp, Dept Radiat Oncol, 123 Ta Pei Rd, Kaohsiung 83301, Taiwan
关键词
Galectin-1; Glioblastoma multiforme; Adjuvant radiotherapy; Radioresistant marker; NEWLY-DIAGNOSED GLIOBLASTOMA; THERAPY-ONCOLOGY-GROUP; RADIATION-THERAPY; PHASE-II; GLIOMA; CELLS; TEMOZOLOMIDE; RAS; GROWTH; ASTROCYTOMA;
D O I
10.1186/s12885-018-4025-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Galectin-1, a radioresistance marker, was found in our previous study to be a prognostic factor for cervical cancer. The aim of current study is to determine the prognostic significance of the galectin-1 expression level in patients with glioblastoma multiforme (GBM) undergoing adjuvant radiotherapy (RT). Methods: We included 45 patients with GBM who were treated with maximal safe surgical resection or biopsy alone followed by adjuvant RT of EQD2 (equivalent dose in 2-Gy fractions) > or = 60 Gy for homogeneous treatment. Paraffin-embedded tissues acquired from the Department of Pathology were analyzed using immunohistochemical staining for galectin-1 expression. The primary endpoint was overall survival (OS). Results: Patients with weak expression had a better median survival (27.9 months) than did those with strong expression (10.7 months; p = 0.009). We compared characteristics between weak and strong galectin-1 expression, and only the expression level of galectin-3 showed a correlation. The group with weak galectin-1 expression displayed a 3-year OS of 27.3% and a 3-year cancer-specific survival (CSS) of 27.3%; these values were only 5.9% and 7.6%, respectively, in the group with strong galectin-1 expression (p = 0.009 and 0.020, respectively). Cox regression was used to confirm that the expression level of galectin-1 (weak vs. strong) is a significant factor of OS (p = 0.020) and CSS (p = 0.022). Other parameters, such as the expression level of galectin-3, Eastern Cooperative Oncology Group (ECOG) performance, gender, surgical method, age = 50 years, tumor size, or radiation field were not significant factors. Conclusion: The expression level of galectin-1 affects survival in patients with GBM treated with adjuvant RT. Future studies are required to analyze the effect of other factors, such as O(6)-methylguanine-DNA methyltransferase (MGMT)-promoter methylation status, in patients with weak and strong galectin-1 expression.
引用
收藏
页数:8
相关论文
共 51 条
[1]   Natural Killer Cells Eradicate Galectin-1-Deficient Glioma in the Absence of Adaptive Immunity [J].
Baker, Gregory J. ;
Chockley, Peter ;
Yadav, Viveka Nand ;
Doherty, Robert ;
Ritt, Michael ;
Sivaramakrishnan, Sivaraj ;
Castro, Maria G. ;
Lowenstein, Pedro R. .
CANCER RESEARCH, 2014, 74 (18) :5079-5090
[2]   A MEDICAL-RESEARCH-COUNCIL TRIAL OF 2 RADIOTHERAPY DOSES IN THE TREATMENT OF GRADE-3 AND GRADE-4 ASTROCYTOMA [J].
BLEEHEN, NM ;
STENNING, SP .
BRITISH JOURNAL OF CANCER, 1991, 64 (04) :769-774
[3]  
BULL JWD, 1957, J FAC RADIOL, V8, P147
[4]   Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis [J].
Bunda, Severa ;
Burrell, Kelly ;
Heir, Pardeep ;
Zeng, Lifan ;
Alamsahebpour, Amir ;
Kano, Yoshihito ;
Raught, Brian ;
Zhang, Zhong-Yin ;
Zadeh, Gelareh ;
Ohh, Michael .
NATURE COMMUNICATIONS, 2015, 6
[5]  
Camby I, 2001, BRAIN PATHOL, V11, P12
[6]  
Campbell Paul M, 2010, J Mol Signal, V5, P18, DOI 10.1186/1750-2187-5-18
[7]   Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: Report from the Radiation Therapy Oncology Group [J].
Chakravarti, A ;
Seiferheld, W ;
Tu, XY ;
Wang, HJ ;
Zhang, HZ ;
Ang, KK ;
Hammond, E ;
Curran, W ;
Mehta, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (02) :318-327
[8]  
Chakravarti A, 2002, CANCER RES, V62, P4307
[9]   RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients [J].
Chakravarti, Arnab ;
Wang, Meihua ;
Robins, H. Ian ;
Lautenschlaeger, Tim ;
Curran, Walter J. ;
Brachman, David G. ;
Schultz, Christopher J. ;
Choucair, Ali ;
Dolled-Filhart, Marisa ;
Christiansen, Jason ;
Gustavson, Mark ;
Molinaro, Annette ;
Mischel, Paul ;
Dicker, Adam P. ;
Bredel, Markus ;
Mehta, Minesh .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (05) :1206-1211
[10]  
Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345